Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice

Esma S. Yolcu, Hong Zhao, Laura Bandura-Morgan, Chantale Lacelle, Kyle B. Woodward, Nadir Askenasy, Haval Shirwan

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Allogeneic islet transplantation is an important therapeutic approach for the treatment of type 1 diabetes. Clinical application of this approach, however, is severely curtailed by allograft rejection primarily initiated by pathogenic effector T cells regardless of chronic use of immunosuppression. Given the role of Fas-mediated signaling in regulating effector T cell responses, we tested if pancreatic islets can be engineered ex vivo to display on their surface an apoptotic form of Fas ligand protein chimeric with streptavidin (SA-FasL) and whether such engineered islets induce tolerance in allogeneic hosts. Islets were modified with biotin following efficient engineering with SA-FasL protein that persisted on the surface of islets for >1 wk in vitro. SA-FasL-engineered islet grafts established euglycemia in chemically diabetic syngeneic mice indefinitely, demonstrating functionality and lack of acute toxicity. Most importantly, the transplantation of SA-FasL-engineered BALB/c islet grafts in conjunction with a short course of rapamycin treatment resulted in robust localized tolerance in 100% of C57BL/6 recipients. Tolerance was initiated and maintained by CD4 +CD25 +Foxp3 + regulatory T (Treg) cells, as their depletion early during tolerance induction or late after established tolerance resulted in prompt graft rejection. Furthermore, Treg cells sorted from graft-draining lymph nodes, but not spleen, of long-term graft recipients prevented the rejection of unmodified allogeneic islets in an adoptive transfer model, further confirming the Treg role in established tolerance. Engineering islets ex vivo in a rapid and efficient manner to display on their surface immunomodulatory proteins represents a novel, safe, and clinically applicable approach with important implications for the treatment of type 1 diabetes.

Original languageEnglish (US)
Pages (from-to)5901-5909
Number of pages9
JournalJournal of Immunology
Volume187
Issue number11
DOIs
StatePublished - Dec 1 2011

Fingerprint

Fas Ligand Protein
Regulatory T-Lymphocytes
Islets of Langerhans
Transplants
Type 1 Diabetes Mellitus
T-Lymphocytes
Islets of Langerhans Transplantation
Streptavidin
Adoptive Transfer
Homologous Transplantation
Graft Rejection
Sirolimus
Therapeutics
Biotin
Immunosuppression
Allografts
Membrane Proteins
Spleen
Transplantation
Lymph Nodes

ASJC Scopus subject areas

  • Immunology

Cite this

Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice. / Yolcu, Esma S.; Zhao, Hong; Bandura-Morgan, Laura; Lacelle, Chantale; Woodward, Kyle B.; Askenasy, Nadir; Shirwan, Haval.

In: Journal of Immunology, Vol. 187, No. 11, 01.12.2011, p. 5901-5909.

Research output: Contribution to journalArticle

Yolcu, Esma S. ; Zhao, Hong ; Bandura-Morgan, Laura ; Lacelle, Chantale ; Woodward, Kyle B. ; Askenasy, Nadir ; Shirwan, Haval. / Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice. In: Journal of Immunology. 2011 ; Vol. 187, No. 11. pp. 5901-5909.
@article{aecf07ef919845c99f73787f055ad9c4,
title = "Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice",
abstract = "Allogeneic islet transplantation is an important therapeutic approach for the treatment of type 1 diabetes. Clinical application of this approach, however, is severely curtailed by allograft rejection primarily initiated by pathogenic effector T cells regardless of chronic use of immunosuppression. Given the role of Fas-mediated signaling in regulating effector T cell responses, we tested if pancreatic islets can be engineered ex vivo to display on their surface an apoptotic form of Fas ligand protein chimeric with streptavidin (SA-FasL) and whether such engineered islets induce tolerance in allogeneic hosts. Islets were modified with biotin following efficient engineering with SA-FasL protein that persisted on the surface of islets for >1 wk in vitro. SA-FasL-engineered islet grafts established euglycemia in chemically diabetic syngeneic mice indefinitely, demonstrating functionality and lack of acute toxicity. Most importantly, the transplantation of SA-FasL-engineered BALB/c islet grafts in conjunction with a short course of rapamycin treatment resulted in robust localized tolerance in 100{\%} of C57BL/6 recipients. Tolerance was initiated and maintained by CD4 +CD25 +Foxp3 + regulatory T (Treg) cells, as their depletion early during tolerance induction or late after established tolerance resulted in prompt graft rejection. Furthermore, Treg cells sorted from graft-draining lymph nodes, but not spleen, of long-term graft recipients prevented the rejection of unmodified allogeneic islets in an adoptive transfer model, further confirming the Treg role in established tolerance. Engineering islets ex vivo in a rapid and efficient manner to display on their surface immunomodulatory proteins represents a novel, safe, and clinically applicable approach with important implications for the treatment of type 1 diabetes.",
author = "Yolcu, {Esma S.} and Hong Zhao and Laura Bandura-Morgan and Chantale Lacelle and Woodward, {Kyle B.} and Nadir Askenasy and Haval Shirwan",
year = "2011",
month = "12",
day = "1",
doi = "10.4049/jimmunol.1003266",
language = "English (US)",
volume = "187",
pages = "5901--5909",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "11",

}

TY - JOUR

T1 - Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice

AU - Yolcu, Esma S.

AU - Zhao, Hong

AU - Bandura-Morgan, Laura

AU - Lacelle, Chantale

AU - Woodward, Kyle B.

AU - Askenasy, Nadir

AU - Shirwan, Haval

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Allogeneic islet transplantation is an important therapeutic approach for the treatment of type 1 diabetes. Clinical application of this approach, however, is severely curtailed by allograft rejection primarily initiated by pathogenic effector T cells regardless of chronic use of immunosuppression. Given the role of Fas-mediated signaling in regulating effector T cell responses, we tested if pancreatic islets can be engineered ex vivo to display on their surface an apoptotic form of Fas ligand protein chimeric with streptavidin (SA-FasL) and whether such engineered islets induce tolerance in allogeneic hosts. Islets were modified with biotin following efficient engineering with SA-FasL protein that persisted on the surface of islets for >1 wk in vitro. SA-FasL-engineered islet grafts established euglycemia in chemically diabetic syngeneic mice indefinitely, demonstrating functionality and lack of acute toxicity. Most importantly, the transplantation of SA-FasL-engineered BALB/c islet grafts in conjunction with a short course of rapamycin treatment resulted in robust localized tolerance in 100% of C57BL/6 recipients. Tolerance was initiated and maintained by CD4 +CD25 +Foxp3 + regulatory T (Treg) cells, as their depletion early during tolerance induction or late after established tolerance resulted in prompt graft rejection. Furthermore, Treg cells sorted from graft-draining lymph nodes, but not spleen, of long-term graft recipients prevented the rejection of unmodified allogeneic islets in an adoptive transfer model, further confirming the Treg role in established tolerance. Engineering islets ex vivo in a rapid and efficient manner to display on their surface immunomodulatory proteins represents a novel, safe, and clinically applicable approach with important implications for the treatment of type 1 diabetes.

AB - Allogeneic islet transplantation is an important therapeutic approach for the treatment of type 1 diabetes. Clinical application of this approach, however, is severely curtailed by allograft rejection primarily initiated by pathogenic effector T cells regardless of chronic use of immunosuppression. Given the role of Fas-mediated signaling in regulating effector T cell responses, we tested if pancreatic islets can be engineered ex vivo to display on their surface an apoptotic form of Fas ligand protein chimeric with streptavidin (SA-FasL) and whether such engineered islets induce tolerance in allogeneic hosts. Islets were modified with biotin following efficient engineering with SA-FasL protein that persisted on the surface of islets for >1 wk in vitro. SA-FasL-engineered islet grafts established euglycemia in chemically diabetic syngeneic mice indefinitely, demonstrating functionality and lack of acute toxicity. Most importantly, the transplantation of SA-FasL-engineered BALB/c islet grafts in conjunction with a short course of rapamycin treatment resulted in robust localized tolerance in 100% of C57BL/6 recipients. Tolerance was initiated and maintained by CD4 +CD25 +Foxp3 + regulatory T (Treg) cells, as their depletion early during tolerance induction or late after established tolerance resulted in prompt graft rejection. Furthermore, Treg cells sorted from graft-draining lymph nodes, but not spleen, of long-term graft recipients prevented the rejection of unmodified allogeneic islets in an adoptive transfer model, further confirming the Treg role in established tolerance. Engineering islets ex vivo in a rapid and efficient manner to display on their surface immunomodulatory proteins represents a novel, safe, and clinically applicable approach with important implications for the treatment of type 1 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=82755190052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82755190052&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1003266

DO - 10.4049/jimmunol.1003266

M3 - Article

VL - 187

SP - 5901

EP - 5909

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 11

ER -